The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity

“…MLL fusion proteins unfold their leukemogenic potential by the recruitment of transcriptional activation complexes, such as SEC leading to phosphorylation of RNA polymerase II and hereby promoting transcriptional activation of oncogenes like MYC [ 23 ]. The transcription factor BRD4 as part of the PAFc is a member of the BET protein family.…”